www.fdanews.com/articles/174863-jj-licenses-hep-b-treatments-from-chia-tai-tianqing
J&J Licenses Hep B Treatments from Chia Tai Tianqing
January 13, 2016
In a rare move, Johnson & Johnson Innovation and Janssen Pharmaceuticals have in-licensed products from a Chinese drugmaker to develop drugs outside that country.
The deal with Chia Tai Tianqing Pharmaceutical Group gives J&J exclusive rights to develop, manufacture and commercialize undisclosed immune-modulating agents for a number of conditions — including chronic hepatitis B — outside China. Financial terms of the deal were not disclosed.